Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

he demographic and blinded safety data from the ongoing Phase III study, the LUX-Lung 1 trial, will be presented at ASCO for the first time.(5)

The LUX-Lung 1 study addresses a critical need for treatment options for NSCLC patients after failure with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study recently moved from Phase IIb into Phase III.(5)

"The LUX-Lung 1 study is important as it investigates BIBW 2992 in a group of patients for whom there are no other approved treatment options. These are patients who have already been through standard first-line or second-line chemotherapy and then received treatment with an EGFR TKI. The LUX-Lung 1 study will evaluate whether BIBW 2992 will extend the lives of these cancer patients,"(5) said Dr. Haehl.

First Presentation of Phase II Data on BIBF 1120 in Ovarian Cancer

Data from a Phase II study of BIBF 1120 in patients with ovarian cancer who responded to at least second-line chemotherapy will be presented at ASCO in Orlando. The study showed a potential delay in disease progression: With BIBF 1120 the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral compound that works by simultaneously inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) -- all factors which are involved in the formation of blood vessels, a process known as angiogenesis.(12,13).

"There is a great need for more effective and well tolerated treatment options for women with ovarian cancer.(14) We have a growing body of evidence that anti-angiogenic agents may represent an important treatment approach for this disease,"(15,16,17) commented Prof. Jonathan A. Ledermann, MD, Professor of Medical Oncology & Director at the Cancer Research UK & UCL Cancer Trials
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... 15 West Pharmaceutical Services, Inc. (NYSE: ... Directors has approved payment of the first-quarter 2010 cash ... paid on February 3, 2010 to shareholders of record ... ,, West is a global manufacturer of components ... seals for vials, and closures and disposable components used ...
(Date:12/15/2009)... 15 SRI International, an independent nonprofit ... of U.S. patent 7,592,021 for a new bioadhesive ... drugs through the human body,s mucous membranes. This ... allows for a much longer release time compared ... Transmucosal delivery is an effective means to introduce ...
(Date:12/15/2009)... SINGAPORE, Dec. 15 ... that it has completed the previously announced ... manufacturer of disposable medical devices ranging from ... surgery. Through its medical segment, Flextronics provides ... device, medical equipment, and pharmaceutical customers. Terms ...
Breaking Medicine Technology:SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 2SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 3SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 4SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System 5Flextronics Completes SloMedical Acquisition 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 1Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 2Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 3Uni H A in France Signs Purchasing Agreement for Masimo SET 28R 29 Pulse Oximetry Products 14907 4Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 1Macomb County Health Department Schedules Communitywide H1N1 Flu Vaccine Clinic Nov 24 61652 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3
... is Designed to Differentiate Squamous From, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Classifying ... of 90 ... Percent., Accurate Diagnosis is Important ... Potential Higher Rates of Severe or Fatal Hemorrhage in Patients With Squamous ...
... 2 DermaGen AB today announced a,cash injection from ... Development and Ostersjostiftelsen. The capital will be used for,the ... be used to initiate a clinical phase 2a study ... has already received approval, and,to further develop the company,s ...
Other Medicine Technology:Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 2Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 3Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 4Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 5Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 6Columbia University Medical Center and Rosetta Genomics Announce Columbia University's Submission of the First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology for Approval to the New York State Department of Health Clinica 7DermaGen AB Receives Over 1 Million Euros From a New Share Issue 2DermaGen AB Receives Over 1 Million Euros From a New Share Issue 3
(Date:12/16/2009)... free nationwide confidential legal consultations for users of Paxil who ... Defects, Attempted Suicide, Suicide and Addiction Issues. Individuals suffering from ... go to the firm’s website at http://www.ennislaw.com and ... ... (PRWEB) December 16, 2009 -- Bloomberg news ...
(Date:12/16/2009)... Foods will be carrying Dr. Shapio,s Help Hair Shake in all of ... ... (PRWEB) December 16, 2009 -- Dr. Larry Shapiro, hair transplant ... Foods stores will be carrying the Help Hair Whey Protein Shake. ... suitable as an adjunct for weight loss programs, working out and muscle ...
(Date:12/15/2009)... successfully developed a new electrophoretic method for detecting ... The technique, using SARCOSYL-PAGE, has specifically enhanced ... performance characteristics of SDS-PAGE for detecting other EPOs. ... grant from the World Anti-Doping Agency (WADA), appear ... and Analysis published by Wiley-Blackwell. , MIRCERA ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected an ... Act that would have helped make prescription drugs ... legal importation of lower priced drugs from abroad. ... by Senators Dorgan, Snowe, McCain, Grassley and Stabenow, ... down the skyrocketing costs of prescription drugs. ,, ...
(Date:12/15/2009)... Bulletin Board: SNKTY), a Life Sciences company engaged in the research, development and commercialization of ... three resolutions that the Company had proposed at the Annual General Meeting of Shareholders held ... of Votes ... Non-, Matter ... For Against ...
Breaking Medicine News(10 mins):Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Florida Whole Foods Stores to Carry Dr. Lawrence Shapiro's Help Hair Shake 2Health News:Researchers discover novel method for detecting MIRCERA 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... the human growth hormone (HGH) industry approaches $2 ... athletic performance, anti-aging and stimulating growth. Unfortunately, many ... of independent review organizations (IROs) whose members see ... medical necessity of growth hormone therapies ( www.nairo.org ...
... Network,s CIO on Helping Organizations Protect Medical Records and Comply ... ... Scottsdale, Ariz. (PRWEB) April 14, 2009 -- With an increasing ... of new challenges to implement administrative, technical and physical security ...
... flow measurement and control provider, announced that it has acquired ... Key Instruments is a flow meter manufacturer based in Trevose, ... flow meters, glass tube flow meters, electronic flow meters, and ... applications. , ...
... 14 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... of a New Drug Application (NDA) to the U.S. ... relapsed or refractory aggressive non-Hodgkin,s lymphoma (NHL). CTI expects ... priority review which if granted could lead to an ...
... allow BlackBerry® devices to securely connect to ActiveSync supported email ... or businesses that require ActiveSync for their mobility solution such ... Suite or the CommuniGate Pro Server. , ... ...
... and PLANO, Texas, April 13 Botox,s arch-nemesis, ... the U.S. cosmetics ring at any moment; whether ... slightly unfamiliar European cousin remains to be seen, ... a significant potential cost savings, is certainly provocative. ...
Other Medicine News:Health News:IROs Help Determine Medical Necessity of Growth Hormone Therapy 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 2Health News:Lumension Webinar Focuses on How to Protect Medical Records, Ensure HIPAA Compliance and Improve Productivity 3Health News:Brooks Instrument Acquires Flow Products Supplier Key Instruments 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 2Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 3Health News:Cell Therapeutics Initiating Rolling NDA Submission for Pixantrone 4Health News:NotifySync™ Provides BlackBerry a Direct Connection to Any Email Platform Supporting Microsoft ActiveSync 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 2Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 3Health News:Botox(R) vs. Reloxin(R) -- the Wrinkle Titans Poised for Battle 4
MP-250N and 300N is a new style power supply. It is a versatile microprocessor power supply for horizontal or vertical gel electrophoresis. The unit is programmable and offers constant voltage and co...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... Power Supply is designed specifically ... extensive programming capabilities, including eight ... for you to set to ... intuitive PowerEase® interface is faster ...
Medicine Products: